Jump to main content
US EPA
United States Environmental Protection Agency
Search
Search
Main menu
Environmental Topics
Laws & Regulations
About EPA
Health & Environmental Research Online (HERO)
Contact Us
Print
Feedback
Export to File
Search:
This record has one attached file:
Add More Files
Attach File(s):
Display Name for File*:
Save
Citation
Tags
HERO ID
455763
Reference Type
Journal Article
Title
Mycophenolate mofetil administration reduces renal inflammation, oxidative stress, and arterial pressure in rats with lead-induced hypertension
Author(s)
Bravo, Y; Quiroz, Y; Ferrebuz, A; Vaziri, ND; Rodriguez-Iturbe, B
Year
2007
Is Peer Reviewed?
Yes
Journal
American Journal of Physiology: Renal Physiology
ISSN:
1931-857X
Volume
293
Issue
2
Page Numbers
F616-F623
Language
English
PMID
17567935
DOI
10.1152/ajprenal.00507.2006
Web of Science Id
WOS:000248459000023
Abstract
Hypertension is a likely consequence of chronic lead exposure in humans, especially in association with reduced renal function and in high risk populations. Numerous studies have demonstrated that oxidative stress plays an important role in the pathogenesis of experimental lead- induced hypertension and we have shown recently that tubulointerstitial immune cell infiltration is a feature of chronic low- dose lead exposure. Since oxidative stress, renal inflammation, and angiotensin activity are closely linked characteristics in experimental models of hypertension, we decided to investigate whether lead- induced hypertension would be ameliorated by suppressing renal inflammation with the immunosuppressive drug mycophenolate mofetil ( MMF). We studied rats exposed for 14 wk to lead acetate ( 100 ppm in the drinking water) that, in addition, received either MMF, 20 mg . kg(-1) . day(-1) by gastric gavage ( Pb. MMF group, n = 12) or vehicle ( Pb group, n = 12). Control rats received MMF alone ( n = 5) or neither lead nor MMF ( n = 6). All rats were killed at the end of the experiment. Low- dose lead exposure resulted in mild to moderate tubular cell damage and a progressive increment in blood pressure, oxidative stress, interstitial accumulation of lymphocytes and macrophages, NF-kappa B activation, and increased renal angiotensin II level. The administration of MMF suppressed the tubulointerstitial accumulation of lymphocytes and macrophages and prevented the hypertension, oxidative stress, and NF-kappa B activation and reduced the heightened renal angiotensin content associated with chronic lead exposure. We conclude that interstitial inflammation plays an important role in lead- induced hypertension.
Keywords
macrophages; lymphocytes; angiotensin II; NF-kappa B
Tags
NAAQS
•
ISA-Lead (2013 Final Project Page)
Considered
Cited
1st Draft
2nd Draft
3rd Draft
Final
Health Effects
•
ISA - Lead (2024 Final Project Page)
Included in Peer Input Draft
Appendix 4 (Cardiovascular Effects)
Included in External Review Draft
Appendix 4 (Cardiovascular Effects)
Included in Final Draft
Appendix 4 (Cardiovascular Effects)
Home
Learn about HERO
Using HERO
Search HERO
Projects in HERO
Risk Assessment
Transparency & Integrity